George Toliver, DO
Family Medicine · Yakima, WANPI 1730157892
Payments from drug & device makers
Across 169 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Bayer$509
- AbbVie$368
- Novo Nordisk$293
- Pfizer$285
- Lilly USA, LLC$217
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,98699%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,980 |
| Bayer | 18 | $509 |
| AbbVie(2 entities) | 20 | $368 |
| Novo Nordisk | 12 | $293 |
| Pfizer | 16 | $285 |
| Lilly USA, LLC | 6 | $217 |
| Otsuka America Pharmaceutical, Inc. | 6 | $199 |
| Amgen | 7 | $152 |
| Viatris Specialty LLC | 6 | $138 |
| Esperion Therapeutics, Inc. | 6 | $129 |
| Mylan Specialty L.p. | 7 | $126 |
| Johnson & Johnson(2 entities) | 5 | $84 |
| Merck | 1 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Neurelis, Inc. | 2 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Exact Sciences | 2 | $46 |
| Edwards Lifesciences | 1 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Novartis | 1 | $23 |
| Corcept Therapeutics | 1 | $19 |
| Echosens North America, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $12 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$545
- AIRSUPRA$246
- ABILIFY MAINTENA$120
- Tresiba$117
How this compares
$5,013 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $72,815 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 71 | $62,961 |
| FarxigaDapagliflozin Propanediol | 62 | $47,339 |
| OzempicSemaglutide | 47 | $44,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $39,136 |
| XareltoRivaroxaban | 38 | $27,614 |
| MounjaroTirzepatide | 25 | $25,900 |
| TradjentaLinagliptin | 26 | $15,921 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 261 | $12,600 |
| Repatha SureclickEvolocumab | 21 | $11,852 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,669 |
| Oxycodone Hcl | 255 | $7,628 |
| JanuviaSitagliptin Phosphate | 11 | $7,254 |
| LinzessLinaclotide | 12 | $6,336 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $285 | $72,815111 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $65 | $62,96171 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,980 | $58,00779 claims |
| Novo NordiskOzempic | $293 | $44,87347 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $12 | $44,84453 claims |
| Johnson & JohnsonXarelto | $84 | $27,61438 claims |
| Lilly USA, LLCMounjaro | $217 | $25,90025 claims |
| Boehringer IngelheimTradjenta | $25 | $15,92126 claims |
| MerckJanuvia | $73 | $7,25411 claims |
| AbbVieLinzess | $368 | $6,33612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Yakima
- Theodore VyeYakima$17K
- Portia JonesYakima$16K
- Vani BremjitYakima$14K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.